Gilead Sciences Inc

GILD: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|JHLOCK|n?!LOCK|%G&Zdr

Gilead Earnings: Raising Our FVE to Account for Significant Inflammation Pipeline Potential

Gilead reported 13% third-quarter product sales growth and 3% non-GAAP diluted earnings per share growth. Management increased 2026 product sales guidance by $900 million at the midpoint based on HIV product outperformance and forecast a steeper non-GAAP EPS decline, largely due to acquisitions.

Sponsor Center